Background. The use of a cytomegalovirus (CMV)-seronegative donor for a CMV-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is generally accepted. However, the importance of donor serostatus in CMV-seropositive patients is controversial.
been developed, allowing better monitoring of patients and early intervention with antiviral therapy [4] [5] [6] . However, despite these advances, patients' CMV serological status still has a strong influence on outcome [7] . It has been shown that the use of a CMV-seronegative donor for a CMV-seronegative patient reduces the risk of transplant-related mortality, especially that caused by infections [8] . The influence of the donor's serological status on outcome after transplant of a CMV-seropositive patient is more controversial [9] [10] [11] . In a previous study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT), we found that using a CMV-seropositive donor improved outcome for a CMVseropositive patient receiving an unrelated donor graft [12] . During the last decade, new transplant technologies have been introduced, such as improved human leukocyte antigen (HLA) typing allowing selection of better-matched unrelated donors and reduced-intensity conditioning (RIC). The aim of this analysis was to analyze the influence of donor CMV serological status on outcome after allogeneic HSCT in a large population of CMV-seropositive and CMV-seronegative patients.
PATIENTS AND METHODS
The EBMT has collected data on patients since the 1970s. For the purpose of this study, we included patients having undergone allogeneic HSCT between 1992 and 2008 and for whom CMV serological status was known for both patient and donor. The EBMT megafile used for this analysis included 54 625 patients who fulfilled these criteria. Patients who had undergone acord blood transplant and transplant for plasma cell disorders or solid tumors were excluded from the analysis. After these exclusions, 49 542 patients remained in the study population; 29 349 were seropositive and 20 193 seronegative. A total of 16 710 seropositive patients had HLA-identical sibling donors, 10 391 had unrelated donors, and 2248 had mismatched family donors. The corresponding numbers for seronegative patients were 10 088 patients with HLA-identical sibling donors, 8801 with unrelated donors, and 1304 with mismatched family donors. Patient characteristics of the study population are shown in Table 1 . Myeloablative and RIC regimens were defined according to guidelines for reporting to the EBMT registry (www.ebmt.org). According to EBMT policy, patients give informed consent for data reporting to the EBMT registry.
Statistical Analysis
CMV serological status of the recipient was used as the main stratification variable; all analyses were done separately for seropositive and seronegative patients. The data analysis approach is the Cox proportional hazards framework. Instead of adjusting for the type of donor (HLA-identical siblings, mismatched family, or unrelated), the final models were stratified by donor type to allow for nonproportionality of the curves as well as a simpler interpretation of the coefficients, in which case interaction with donor type does not apply.
The following factors were included in the analyses: calendar year of HSCT (continuous), patient age (continuous), diagnosis (acute leukemia, chronic leukemia, lymphoma, myelodysplastic syndrome or myeloproliferative disorder, and nonmalignant disease), stem cell source, country where the transplant was performed, patient and donor sex (as well as their interaction), conditioning intensity (according to the EBMT definitions), and use of T-cell depletion. We have previously shown that the CMV serological status of the donor and the recipient varied significantly between different parts of Europe [13] . The variable "country" was therefore divided as follows: the Netherlands plus Belgium, France, Spain, Italy, United Kingdom, the Nordic countries, Germany, and other countries. The T-cell depletion variable was categorized as no T-cell depletion, in vivo (use of anti-thymocyte globulin or alemtuzumab), or ex vivo (with or without addition of in vivo T-cell depletion).
All conclusions are based on final models with patient age but without donor age due to the loss of power caused by a high percentage of missing donor age values. However, to exclude substantial bias due to donor age, we also fit the data to include this parameter so as to verify (taking into account the wider confidence intervals [CIs] due to the reduced sample size) our results.
Cox models were constructed, stratified by donor type, from which the estimated effects were quantified as a hazard ratio (HR) to test the association between CMV positivity of the donor with overall survival, relapse incidence, relapse-free survival, and nonrelapse mortality. Each model contained interaction terms for donor positivity with "T-cell depletion" and "conditioning intensity." Backward selection of these interaction terms retained only terms with a P value <.10. In such a case, separate HRs are reported as well as the P value of the interaction term.
Although the HRs are all based on the Cox model framework, construction of curves was performed properly in the competing risk framework, leading to simultaneous estimates for nonrelapse mortality, "death after relapse," "alive with relapse," and "alive without relapse" (and thus of "overall survival" and "relapse-free survival" by combining some of these estimates). Univariate and bivariate curves are presented but no statistical tests were performed to compare the curves themselves in a model approach (eg, Fine and Gray). We also compared the crude overall survival of those who entered the analysis models and those who did not. We did apply the patient population selection criteria (eg, on year and diagnosis) but retained the patients with missing covariates and/or missing donor serology for a comparison (Supplementary Figures 1A and 1B) .
For the analysis of causes of death, a logistic regression approach was used, conditioning on death without relapse between transplant and 60 months' follow-up, thus avoiding the notion of censoring. A hierarchical definition of cause of death was applied: any death preceded by a relapse was classified as "relapse"; if not a relapse but a secondary malignancy was coded, the cause was classified as such; if neither happened but the death was explicitly coded as being caused by graftvs-host disease, that cause was taken; if none of these were observed and an infection was explicitly mentioned as the cause of death, then the cause was classified as "infection." If none of these applied but the cause of death was coded as rejection/ poor graft function, veno-occlusive disease, or hemorrhage, we used "organ failure" as the cause of death; finally, all unclassified deaths were coded as "other cause."
Association between CMV donor positivity and cause of death was assessed by a simple χ 2 analysis in a 2 × 6 table. To study death due to infection in detail, the subset of patients was selected, who were all classified as "cause of death = infection." Conditional on having died due to infection, the following analyses were performed to assess possible associations between CMV donor positivity and the type of infection: bacterial, viral, or fungal. For each patient, we used 2 approaches: (1) an infection (bacterium or virus or fungus) given as the only cause of death vs all other deaths due to infection (possibly including the same pathogen); (2) the pathogen type under investigation given as a cause of death either as single infection or as a part of a multipathogen infection vs death due to infection but not specifying the pathogen(s). Both approaches lead to the quantification of the association as an odds ratio in a 2 × 2 table (likelihood ratio test).
RESULTS

CMV-Seronegative Patients
HLA-Identical Sibling Donors and Mismatched Family Donors
The estimated 5-year survival (Kaplan-Meier) after HLAidentical sibling HSCT was 54% for patients with CMVseropositive donors and 59% for patients with CMV-seronegative donors ( Figure 1A ). In a multivariate Cox regression model, donor CMV serological status had a borderline significant effect on overall survival after HLA-identical sibling HSCT (HR, 1.07 [95% CI, 1.00-1.14]; P = .06) after adjusting for calendar year of HSCT, donor sex, patient age, diagnosis, stem cell source, country where the transplant was performed, patient sex, conditioning intensity, and use of T-cell depletion (in vivo or ex vivo) ( Table 2 ). The inclusion of donor age in the model reduced the HR slightly (data not shown). There was no significant effect of the donor CMV serological status on relapse-free survival, nonrelapse mortality, or relapse incidence (Table 2) . There was no effect on outcome of CMV serological status in patients transplanted from mismatched family donors. The estimated 5-year survival (Kaplan-Meier) was 44% for patients with CMV-seropositive donors and 47% for patients with CMV-seronegative donors (data not shown).
Unrelated Donors
The estimated 5-year survival (Kaplan-Meier) was 45% for patients with CMV-seropositive donors and 50% for patients with CMV-seronegative donors ( Figure 1B) . CMV-seronegative patients receiving grafts from CMV-seropositive donors had in a multivariate Cox regression model significantly lower overall survival (HR, 1.13 [95% CI, 1.06-1.21]; P < .0001) compared with CMV-seronegative patients receiving grafts from CMVseronegative donors (Table 2) . This difference in survival was also seen with the inclusion of donor age in the model (data not shown). There was also a decreased relapse-free survival (HR, 1.10 [95% CI, 1.03-1.19]; P < .003) and an increased nonrelapse mortality (HR, 1.14 [95% CI, 1.04-1.24]; P < .01) in patients receiving grafts from CMV-seropositive donors compared with patients receiving grafts from CMV-seronegative donors. The same effect was seen also with donor age in the model, although the HR was somewhat reduced. Furthermore, when we restricted the sample to patients transplanted from the year 2000 onward (n = 14 231) to get a sample more consistent with today's practice, the same negative effects of using a CMVseropositive unrelated donor were consistently observed.
Causes of Death
A total of 2697 of 5857 (46.0%) patients died in the CMVseropositive donor group and 5955 of 14 336 (41.5%) died in the CMV-seronegative donor group. Of the 2697 patients with a seropositive donor, 1524 (57%) patients died of transplantrelated causes and 1173 (43%) from the underlying disease in the CMV-seropositive donor group. The corresponding numbers in the CMV-seronegative donor group were 3243 (54%) of transplant-related causes and 2712 (46%) of the underlying disease. The distribution of causes of nonrelapse mortality between patients with CMV-seropositive or CMV-seronegative donors was similar (data not shown). Although more patients died from viral infections in the CMV-seropositive donor group, this was not significant (5.8% vs 4.9%; P = .21).
CMV-Seropositive Patients
HLA-Identical Sibling or Mismatched Family Donors
Donor CMV serological status had no significant effect on overall survival, relapse-free survival, nonrelapse mortality, or relapse incidence ( Table 2 ). The estimated 5-year overall survival (Kaplan-Meier) after HLA-identical sibling HSCT was 52% both for patients with CMV-seropositive donors and those with CMV-seronegative donors. The corresponding KaplanMeier survival estimates were 39% and 34% for patients with HLA-mismatched family donors (not significant in univariate or multivariate analysis). There was no difference when donor age was included in the models (data not shown).
Unrelated Donors
The estimated 5-year survival (Kaplan-Meier) after unrelated donor HSCT was 43% for patients with CMV-seropositive donors and 41% for patients with CMV-seronegative donors. When simply adjusting for conditioning intensity in the Cox model (ie, averaging the effects over both intensity categories), CMV-seropositive patients receiving grafts from CMVseropositive donors had a nonsignificant (but beneficial) effect on overall survival (HR, 0.96 [95% CI, .91-1.01]; P = .11; Table 2 ) and a significantly beneficial effect on nonrelapse mortality (HR, 0.94 [95% CI, .87-1.00]; P = .05) compared with CMVseropositive patients receiving grafts from CMV-seronegative donors. The HR for overall survival decreased slightly more after addition of donor age. Ex vivo T-cell depletion had a negative impact on overall survival (P < .01) and relapse-free survival (P < .01). We found, however, a significant interaction between donor CMV serological status and conditioning intensity showing that merely adjusting for such intensity is an inappropriate and biased assessment of the CMV effect (which then depends on the actual relative contribution of RIC to the total number of transplants). We therefore estimated the effect separately in patients having received myeloablative or RIC regimens. The 5-year survival estimate was 44% for patients with CMV- seropositive donors and 41% for patients with CMV-seronegative donors who had undergone myeloablative conditioning (Figure 2A ). The corresponding survival estimates in patients who had undergone HSCT with RIC were 40% and 39%, respectively ( Figure 2B ). In multivariate modeling, CMVseropositive patients with seropositive donors who received myeloablative conditioning had significantly improved overall survival (HR, 0.91 [95% CI, .86-.97]; P < .01) and a decreased nonrelapse mortality (HR, 0.88 [95% CI, .81-.95]; P < .01). A summary of the effects is shown in Table 3 , and the univariate and multivariate HR estimates for overall survival and nonrelapse mortality are shown in Table 4 . A positive effect on overall survival was also seen when the analysis was restricted to patients with myeloablative conditioning transplanted from the year 2000 onward (n = 21 813; HR, 0.91 [95% CI, .85-.98]; P = .02). In contrast, no significant effect of donor CMV status was seen in patients receiving RIC regimens, although the HRs were between 1.05 and 1.10.
Causes of Death
A total of 9024 of 19 385 (46.6%) patients died in the CMVseropositive donor group, and 492 of 9964 (49.4%) died in the CMV-seronegative donor group. In the CMV-seropositive donor group, 5109 (57%) patients died of transplant-related causes; in the CMV-seropositive donor group, 3915 (43%) died from the underlying disease. The corresponding numbers in the CMV-seronegative donor group were 2915 (59%) of transplantrelated causes and 2011 (41%) of the underlying disease. There were differences in the causes of death between patients with CMV-seropositive or CMV-seronegative donors. Patients who received grafts from CMV-seronegative donors were more likely to die from viral infection given as the only cause of death (6.2% vs 4.7%; P = .005) or where a viral pathogen was included as a part of a mixed infection with different organisms (8.3% vs 6.4%; P < .01). This increase in risk for death from viral infections was found in all 3 donor groups, although it was significantly different only in patients receiving unrelated donor grafts (data not shown). There was no difference in the rates of patients dying from bacterial or fungal infections (data not shown).
DISCUSSION
CMV is one of the major causes of transplant-related mortality in patients undergoing allogeneic HSCT [14] [15] [16] . One of the key factors for outcome has been patient CMV serological status, especially in those receiving unrelated-donor transplants [7, 9, [17] [18] [19] [20] [21] . CMV-seropositive patients have a poorer outcome than CMV-seronegative patients despite improvement in preventive strategies against CMV disease such as antiviral prophylaxis and preemptive therapy [7, 19] . The effect of donor serostatus in CMV-seropositive patients remains a controversial issue. CMV can be transmitted from a seropositive donor to a seronegative patient and therefore the importance of selecting a CMV-seronegative donor for a CMV-seronegative patient has been recognized for a long time [22] and was confirmed in a recent study from the EBMT analyzing outcome of patients with acute leukemia [21] , but the impact of different donor categories was not analyzed. In our study, we were only able to verify this negative impact on overall survival in patients receiving grafts from unrelated donors. This was also true when the analysis was restricted to patients transplanted from the year 2000 onward. In sibling donors, there were similar tendencies, but donor CMV serological status was not an independent risk factor for outcome. This is of practical importance as the option to select a matched sibling donor on CMV serological status rarely exists. It should be noted that there was a negative impact of donor age in the mismatched family donor subgroup; because haploidentical family donors are being increasingly used [23, 24] , this might be important when selecting the best donors when different options exist. In our study, there was an increase in the proportion of patients dying from transplant-related causes if the donor was CMV seropositive vs CMV seronegative. This might have been explained by the observation of Nichols et al that the mortality from fungal and bacterial infections was increased in this donor/recipient combination [8] . However, we were unable to show that these particular causes of death were more common in CMV-seronegative patients receiving CMV-seropositive donor grafts. However, it should be recognized that a retrospective analysis of the causes of death reported from many centers should be interpreted with caution.
Although the importance of the negative effect of a CMVmismatched donor for CMV-seronegative patients has been generally accepted, the influence of a similar mismatch in a CMV-seropositive patient has remained controversial. Kollman et al, in a large study from the National Marrow Donor Program, reported that increasing bone marrow donor age was a significant risk factor for decreased survival, but no effect of CMV donor serological status could be found [11] . In our previous study, we detected a strong influence of donor CMV seropositivity on outcome in unrelated donor transplants [12] . Patients receiving grafts from CMV-seropositive unrelated donors had improved survival, event-free survival, and reduced nonrelapse mortality. These effects were also abrogated by T-cell depletion. Since these 2 studies were published, several observations have been made regarding the negative effect of CMV-seronegative donors for CMV-seropositive patients on directly CMV-associated outcomes; in particular, delayed CMV-specific immune reconstitution [25] [26] [27] [28] [29] , repeated CMV reactivations [26, 30] , requirement of additional courses of antiviral therapy [29] , late CMV recurrence [31] , and development of CMV disease [26, 32, 33] .
In the current analysis, we show that using a CMV-seronegative unrelated donor for a CMV-seropositive patient did not have an effect on overall survival (HR, 0.96 [95% CI, .91-1.01]; P = .11). However, there was a strong interaction between the CMV serological status of the donor and conditioning intensity. When accounting for this interaction by estimating the CMV donor effect of type of conditioning intensity, we found something new; namely, that there was a protective effect of donor seropositivity resulting in improved overall survival in patients having received myeloablative conditioning, whereas there was no such effect in patients receiving RIC (the discrepancy between the 2 effects being significant in itself ). The effect is most likely mediated through retention of CMV-specific recipient T-cell function in patients receiving RIC. This fits well with previous observations that RIC is associated with better early immune reconstitution and a lower risk for CMV infection early after HSCT [34] and a lower risk for high-grade CMV infection [35] . In contrast to our previous study, we were unable to see an effect of in vivo or in vitro T-cell depletion on the impact of CMV serological status on overall survival or nonrelapse mortality in patients receiving either myeloablative or reduced-intensity conditioning.
In addition, CMV-seropositive patients receiving grafts from CMV-seronegative donors were more likely to die from viral infections. Although the EBMT registry does not make provision for distinction between different viral infections as the cause of death, the finding suggests that the presence of CMV-specific T cells is the key factor mediating the protective effect of donor serological status on overall survival.
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